Merus N.V. Overview
Pro stress-test →Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®, manufactured using industry standard processes and observed to have features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Founded in 2003, the company has focused on developing innovative bispecific antibody therapeutics.
Strategic Profile
Pro stress-test →Merus's lead asset is petosemtamab, a breakthrough therapy in Phase 3 development for head and neck cancer. In September 2025, Genmab announced an acquisition of Merus for USD 97.00 per share in an all-cash transaction representing USD 8.0 billion, with the tender offer anticipated to close by early Q1 2026. As of December 2025, the tender offer expired on December 11, 2025, and Genmab's subsidiary accepted approximately 94.2% of Merus's outstanding share capital.
Competitive Landscape
Pro stress-test →Investors comparing MRUS often look at related companies including TG Therapeutics Inc (TGTX), CRISPR Therapeutics (CRSP), Legend Biotech Corp (LEGN), PTC Therapeutics (PTCT), and Axsome Therapeutics (AXSM). Merus competes in the immuno-oncology and bispecific antibody space against both clinical-stage biotech firms and established pharmaceutical companies developing multispecific therapeutics.
Industry Context
Merus N.V. operates in Biotechnology / Oncology Therapeutics.
Key facts
Founded: 2003 · Headquarters: Utrecht, Netherlands · Employees: 201-500 · Revenue: $36.1M · Market cap: $6.8B